Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy | 3 | 2015 | 1858 | 0.480 |
Why?
|
| Paraproteins | 1 | 2011 | 41 | 0.370 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 6 | 2023 | 2452 | 0.370 |
Why?
|
| Plasmacytoma | 1 | 2011 | 123 | 0.350 |
Why?
|
| Mediastinal Neoplasms | 4 | 2015 | 429 | 0.340 |
Why?
|
| Radiation Oncology | 3 | 2024 | 557 | 0.310 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 404 | 0.310 |
Why?
|
| Hodgkin Disease | 6 | 2015 | 1488 | 0.310 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 16226 | 0.290 |
Why?
|
| Endovascular Procedures | 2 | 2023 | 469 | 0.270 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2023 | 588 | 0.270 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2023 | 519 | 0.260 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2015 | 1736 | 0.260 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 379 | 0.250 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 694 | 0.240 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2018 | 2168 | 0.240 |
Why?
|
| Mammography | 2 | 2014 | 1045 | 0.220 |
Why?
|
| Radiation Injuries | 3 | 2018 | 1472 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2015 | 16606 | 0.210 |
Why?
|
| Mastodynia | 1 | 2022 | 14 | 0.210 |
Why?
|
| Preoperative Care | 2 | 2011 | 1550 | 0.210 |
Why?
|
| Stomach Neoplasms | 3 | 2012 | 2317 | 0.210 |
Why?
|
| Breast | 4 | 2021 | 1379 | 0.200 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2668 | 0.200 |
Why?
|
| Algorithms | 2 | 2014 | 3922 | 0.200 |
Why?
|
| Neck | 1 | 2023 | 386 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 10354 | 0.180 |
Why?
|
| Oncologists | 1 | 2022 | 135 | 0.170 |
Why?
|
| Lymph Nodes | 3 | 2021 | 3069 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2023 | 7788 | 0.170 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 2286 | 0.170 |
Why?
|
| Radiation Oncologists | 1 | 2019 | 31 | 0.160 |
Why?
|
| Community Health Centers | 1 | 2019 | 50 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 612 | 0.160 |
Why?
|
| Doxorubicin | 7 | 2015 | 3131 | 0.160 |
Why?
|
| Deoxycytidine | 2 | 2011 | 1378 | 0.160 |
Why?
|
| Cosmetics | 1 | 2018 | 13 | 0.160 |
Why?
|
| Heart | 4 | 2014 | 1214 | 0.160 |
Why?
|
| Brachytherapy | 2 | 2018 | 1005 | 0.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2012 | 331 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2014 | 550 | 0.150 |
Why?
|
| Vidarabine | 1 | 2003 | 1383 | 0.150 |
Why?
|
| Prednisone | 4 | 2015 | 1037 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2021 | 6876 | 0.140 |
Why?
|
| Cyclophosphamide | 5 | 2015 | 3231 | 0.140 |
Why?
|
| Middle Aged | 24 | 2022 | 90349 | 0.140 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 2198 | 0.140 |
Why?
|
| Vincristine | 4 | 2015 | 1572 | 0.130 |
Why?
|
| Software | 1 | 2023 | 1383 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Telemedicine | 1 | 2022 | 546 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 864 | 0.120 |
Why?
|
| Retrospective Studies | 14 | 2021 | 39731 | 0.120 |
Why?
|
| Lung | 3 | 2015 | 3293 | 0.120 |
Why?
|
| Female | 28 | 2022 | 148992 | 0.120 |
Why?
|
| Physicians | 1 | 2023 | 870 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2015 | 1068 | 0.120 |
Why?
|
| Cranial Nerve Diseases | 1 | 2014 | 77 | 0.110 |
Why?
|
| Aged | 17 | 2021 | 73421 | 0.110 |
Why?
|
| Humans | 35 | 2024 | 271636 | 0.110 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 31032 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 780 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 960 | 0.110 |
Why?
|
| Treatment Outcome | 12 | 2023 | 33846 | 0.110 |
Why?
|
| Craniospinal Irradiation | 1 | 2014 | 133 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 313 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 5 | 2015 | 879 | 0.100 |
Why?
|
| Etoposide | 3 | 2015 | 905 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1236 | 0.100 |
Why?
|
| Organs at Risk | 4 | 2023 | 560 | 0.100 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 9042 | 0.100 |
Why?
|
| Radiotherapy Dosage | 6 | 2018 | 4003 | 0.100 |
Why?
|
| Observer Variation | 2 | 2014 | 720 | 0.090 |
Why?
|
| Radiopharmaceuticals | 3 | 2015 | 1338 | 0.090 |
Why?
|
| Adult | 15 | 2015 | 81791 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2015 | 1259 | 0.090 |
Why?
|
| Rituximab | 5 | 2015 | 1588 | 0.090 |
Why?
|
| Splenic Neoplasms | 1 | 2010 | 125 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2023 | 371 | 0.090 |
Why?
|
| Time Factors | 6 | 2021 | 13116 | 0.080 |
Why?
|
| Prosthesis Design | 2 | 2023 | 663 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 3852 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2007 | 4967 | 0.080 |
Why?
|
| Young Adult | 8 | 2015 | 22094 | 0.080 |
Why?
|
| Patient Positioning | 1 | 2010 | 195 | 0.080 |
Why?
|
| Efficiency | 1 | 2008 | 93 | 0.080 |
Why?
|
| Clavicle | 1 | 2007 | 67 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2014 | 1188 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2022 | 2270 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2010 | 369 | 0.070 |
Why?
|
| Risk Factors | 5 | 2023 | 18016 | 0.070 |
Why?
|
| Male | 17 | 2021 | 128836 | 0.070 |
Why?
|
| Neoplasms | 3 | 2024 | 15903 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2015 | 2334 | 0.070 |
Why?
|
| Leukemia | 1 | 2014 | 1721 | 0.070 |
Why?
|
| Survival Rate | 3 | 2021 | 12530 | 0.060 |
Why?
|
| Stents | 2 | 2023 | 1014 | 0.060 |
Why?
|
| Dexamethasone | 3 | 2015 | 1496 | 0.060 |
Why?
|
| Esophagus | 2 | 2023 | 563 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 898 | 0.060 |
Why?
|
| Prognosis | 5 | 2018 | 22525 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 15254 | 0.060 |
Why?
|
| Incidence | 2 | 2021 | 5856 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2011 | 7244 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 4495 | 0.060 |
Why?
|
| Mastectomy, Segmental | 2 | 2022 | 1047 | 0.060 |
Why?
|
| Peer Review | 1 | 2024 | 83 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 917 | 0.060 |
Why?
|
| Parotid Gland | 1 | 2023 | 117 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 241 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 2029 | 0.050 |
Why?
|
| Vinblastine | 2 | 2015 | 462 | 0.050 |
Why?
|
| Bleomycin | 2 | 2015 | 482 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 596 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 53 | 0.050 |
Why?
|
| Stomatitis | 1 | 2003 | 193 | 0.050 |
Why?
|
| Esophagitis | 1 | 2003 | 210 | 0.050 |
Why?
|
| Dacarbazine | 2 | 2015 | 505 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2015 | 1432 | 0.050 |
Why?
|
| Methotrexate | 2 | 2015 | 1027 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2008 | 2254 | 0.050 |
Why?
|
| Body Image | 1 | 2021 | 123 | 0.040 |
Why?
|
| Remission Induction | 3 | 2014 | 3645 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1439 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 10259 | 0.040 |
Why?
|
| Seroma | 1 | 2018 | 77 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2003 | 1280 | 0.040 |
Why?
|
| Cytarabine | 2 | 2015 | 2014 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 309 | 0.040 |
Why?
|
| Neoplasm Staging | 4 | 2015 | 13989 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 2202 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2015 | 2035 | 0.030 |
Why?
|
| Edema | 1 | 2018 | 263 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2015 | 2118 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 2051 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 746 | 0.030 |
Why?
|
| Facial Nerve Diseases | 1 | 2014 | 21 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2003 | 2431 | 0.030 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 618 | 0.030 |
Why?
|
| Recurrence | 1 | 2003 | 4884 | 0.030 |
Why?
|
| Texas | 2 | 2019 | 6434 | 0.030 |
Why?
|
| Quality of Life | 2 | 2021 | 4745 | 0.030 |
Why?
|
| Optic Nerve Diseases | 1 | 2014 | 111 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 7971 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2007 | 14653 | 0.030 |
Why?
|
| Disease Progression | 2 | 2014 | 6905 | 0.030 |
Why?
|
| Age Factors | 2 | 2014 | 5509 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2015 | 6986 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 1327 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 751 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 690 | 0.020 |
Why?
|
| Cause of Death | 1 | 2015 | 786 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 1587 | 0.020 |
Why?
|
| Dehydration | 1 | 2011 | 90 | 0.020 |
Why?
|
| Adolescent | 4 | 2015 | 32609 | 0.020 |
Why?
|
| United States | 2 | 2021 | 16036 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2012 | 231 | 0.020 |
Why?
|
| Karyotype | 1 | 2011 | 237 | 0.020 |
Why?
|
| Anorexia | 1 | 2011 | 147 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2049 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2010 | 101 | 0.020 |
Why?
|
| Capecitabine | 1 | 2011 | 390 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2004 | 609 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2335 | 0.020 |
Why?
|
| Pain | 1 | 2018 | 1696 | 0.020 |
Why?
|
| Nausea | 1 | 2011 | 540 | 0.020 |
Why?
|
| Consensus | 1 | 2014 | 1115 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 704 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 433 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2011 | 476 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2011 | 671 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 3460 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 3538 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 4352 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 5209 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 1010 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1424 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2023 | 5688 | 0.020 |
Why?
|
| Protons | 1 | 2010 | 483 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 1988 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 5113 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2010 | 643 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 5195 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6266 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4391 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 2034 | 0.010 |
Why?
|
| Chlorambucil | 1 | 2003 | 26 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2018 | 13385 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 5919 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 207 | 0.010 |
Why?
|
| Kidney | 1 | 2011 | 2265 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3976 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 1950 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 895 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2010 | 9323 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9467 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 7292 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 935 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 5420 | 0.010 |
Why?
|